Willow vs Ro.co: Oral GLP-1, support, and pricing compared
Willow vs Ro.co is a comparison of two telehealth-first weight management options that both require a licensed clinician to determine medical appropriateness. Early verdict: Ro.co is the clearer choice for patients seeking the FDA-approved Wegovy pill and a low $39 online start, while Willow focuses on structured progress tracking and follow-up support with a higher starting price of 299.
Explore Willow’s structured program
Quick comparison snapshot
Both platforms deliver telehealth weight management and require clinician review. Key differences are pricing, access to the FDA-approved Wegovy pill, and the depth of behavioral follow-up and tracking.
How they differ: price and entry cost
Price is the most distinct difference. Ro.co advertises a Get Started Online price of just 39. Willow’s starting price is 299. Ro.co’s marketing notes that ongoing branded medication costs can be significantly higher than compounded alternatives, and Willow’s materials state a higher monthly entry pricing for some plans.
How they differ: medication type and regulatory status
Ro.co offers access to the Wegovy pill, described as the first and only FDA-approved oral GLP-1 weight loss medication, and emphasizes that it provides finished, FDA-approved products rather than compounded medications. Willow positions an oral GLP-1 program but notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Both platforms specify treatment is available only when a licensed clinician determines it is medically appropriate.
How they differ: program support and features
Willow frames its offering as a structured weight management journey with licensed telehealth teams, progress tracking tools, and follow-up consultations to convert GLP-1 efficacy into sustainable outcomes. Ro.co highlights being a full-service telehealth platform with brand trust and notes no hidden fees and pricing disclosure before finishing a consultation. Willow’s strength is structured digital follow-up; Ro.co’s strength is access to an FDA-approved oral option without injections.
See Willow’s progress tracking features
Regulatory notes and product clarity
Ro.co emphasizes regulatory clarity by offering an FDA-approved finished medication, while Willow alerts users that compounded medications, when offered, are not FDA-approved. Both sources state treatment is subject to clinician review and that compounded products are not reviewed by FDA for safety, effectiveness or quality.
Side-by-side table
| Criteria | Willow | Ro.co |
|---|---|---|
| Starting price | 299 | Get Started Online for Just $39 |
| Medication type | Oral GLP-1 program; compounded medications may be offered and are not FDA-approved | Wegovy pill, FDA-approved oral GLP-1; finished medication, not compounded |
| Program support | Licensed telehealth team, progress tracking tools, follow-up consultations | Full-service telehealth platform; pricing disclosed before consultation; no hidden fees claimed |
| Best for | Users who want structured digital follow-up | Online GLP-1 weight loss care, injection-averse patients |
| Regulatory note | Compounded medications, when offered, are not FDA-approved and are not reviewed by FDA | Offers an FDA-approved oral GLP-1; compounded medications are not FDA-approved |
Clinical access and patient experience
Both require clinician review to determine medical appropriateness. Willow emphasizes converting medication effects into long-term outcomes via behavioral scaffolding and follow-up. Ro.co emphasizes the practical benefit of an oral, FDA-approved option for patients who avoid injections and highlights brand trust and transparent pricing practices.
Bottom line and recommendation
Willow vs Ro.co comes down to priorities. Choose Ro.co if access to the FDA-approved Wegovy pill, a low $39 online start, and a finished, non-compounded oral option matter most. Choose Willow if you prioritize a structured digital program with licensed telehealth support, progress tracking tools, and follow-up consultations and accept a higher starting price of 299. Both platforms require a licensed clinician to determine medical appropriateness, and compounded medications are not FDA-approved when offered.